BY
BYSI.US BeyondSpring Inc
- Market cap
- USD 24.7M
- P/E
- -
- P/B
- 5.38x
- ROE
- -39.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BYSI.US undervalued?
Graham numberThe Graham number of BeyondSpring Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BeyondSpring Inc fundamental analysis
No fundamental analysis for BeyondSpring Inc yet.
BeyondSpring Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer…
Full company profileBeyondSpring Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BeyondSpring Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 180K | 1.35M | 1.35M | 1.75M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -18.0K | -32.0K | -48.0K | -77.0K | 180K | 1.35M | 1.35M | -302K | -285K | -87.0K | -76.0K |
| Operating Income | -12.4M | -98.0M | -57.5M | -40.3M | -64.2M | -66.2M | -37.2M | -15.1M | -8.75M | -8.95M | -7.93M |
| EBITDA | -12.4M | -97.9M | -57.5M | -40.1M | -63.7M | -64.5M | -35.9M | -13.6M | -8.48M | -8.54M | -7.54M |
| Net Income | -12.0M | -91.8M | -54.9M | -38.1M | -61.0M | -64.2M | -33.3M | -21.0M | -11.1M | -7.99M | -6.02M |
| EPS | -0.71 | -4.40 | -2.42 | -1.55 | -2.03 | -1.64 | -0.85 | -0.54 | -0.28 | -0.20 | - |
| Balance Sheet | |||||||||||
| Total Assets | 14.9M | 32.8M | 7.06M | 44.6M | 117M | 81.6M | 46.2M | 24.8M | 34.3M | 25.9M | 19.9M |
| Total Liabilities | 2.61M | 4.79M | 16.4M | 13.4M | 25.2M | 60.7M | 49.2M | 48.3M | 48.6M | 49.9M | 4.62M |
| Shareholders' Equity | 12.2M | 27.1M | -7.77M | 30.3M | 88.3M | 20.9M | -5.98M | -26.8M | -32.9M | -32.2M | 15.2M |
| Cash & Short-term Investments | 11.7M | 30.6M | 3.89M | 35.9M | 110M | 72.4M | 37.3M | 15.3M | 2.92M | 12.6M | 580K |
| Total Debt | 210K | - | - | 3.94M | 4.31M | 3.58M | 4.96M | 847K | 589K | 320K | 79.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.7M | -28.8M | -40.0M | -48.2M | -43.7M | -47.2M | -28.2M | -16.5M | -16.4M | -20.0M | -14.2M |
| Capital Expenditure | 64.0K | 76.0K | 207K | 4.00K | 52.0K | 2.84M | 34.0K | 100K | 224K | 50.0K | 0.00 |
| Free Cash Flow | -13.8M | -28.9M | -40.2M | -48.2M | -43.8M | -50.1M | -28.2M | -16.6M | -16.7M | -20.1M | -14.2M |
| Ratios | |||||||||||
| ROE | -98.8% | -338.9% | - | -125.8% | -69.0% | -306.7% | - | - | - | - | -39.5% |
| ROA | -80.6% | -279.5% | -776.9% | -85.5% | -52.1% | -78.6% | -72.0% | -84.8% | -32.4% | -30.8% | -30.3% |
| Net Profit Margin | - | - | - | - | -33,873.9% | -4,750.5% | -2,463.3% | -1,200.8% | - | - | - |
| Debt to Equity | 0.02x | - | - | 0.13x | 0.05x | 0.17x | - | - | - | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BeyondSpring Inc dividends
BeyondSpring Inc has not paid dividends in the last 9 fiscal years.
Who owns BeyondSpring Inc
- Insiders 17.40%
- Institutions 13.15%
- Public & others 69.45%
- Shares outstanding 41.1M
- Free float 32.7M
Top funds holding BYSI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 352K | 0.86% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 157K | 0.38% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 96.5K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 66.1K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 42.9K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 22.3K | 0.05% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 7.27K | 0.02% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 4.80K | 0.01% | 0.00% | Sep 2026 |
| BlackRock Advtg Asia ex Jpn Eq D GBP Acc | 3.36K | 0.01% | 0.00% | Jul 2026 |
| Guggenheim Active Allocation Fund | 266.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding BYSI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Decheng Capital LLC | 3.80M | 9.24% | 0.00% | Jun 2026 |
| BlackRock Inc | 673K | 1.64% | +3.61% | Jun 2026 |
| Vanguard Capital Management, LLC | 626K | 1.52% | +3.05% | Jun 2026 |
| Geode Capital Management, LLC | 368K | 0.89% | -2.03% | Jun 2026 |
| State Street Corp | 231K | 0.56% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 181K | 0.44% | +0.71% | Jun 2026 |
| UBS Group AG | 63.0K | 0.15% | +5,287.35% | Jun 2026 |
| Northern Trust Corp | 62.0K | 0.15% | -10.46% | Jun 2026 |
| Meridian Wealth Management, LLC | 15.0K | 0.04% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 10.9K | 0.03% | -1.80% | Jun 2026 |
| Vanguard Global Advisers, LLC | 4.80K | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.57K | 0.01% | 0.00% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 2.88K | 0.01% | 0.00% | Jun 2026 |
| Trifecta Capital Advisors LLC | 1.50K | 0.00% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.47K | 0.00% | +45.00% | Jun 2026 |
| SIMPLEX TRADING, LLC | 1.17K | 0.00% | +34.84% | Jun 2026 |
| JPMorgan Chase & Co | 319.00 | 0.00% | +7.41% | Jun 2026 |
| SBI Securities Co Ltd | 76.00 | 0.00% | -12.64% | Jun 2026 |
| Barclays PLC | 19.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 9.00 | 0.00% | 0.00% | Jun 2026 |
BeyondSpring Inc company profile
- Company name
- BeyondSpring Inc
- Ticker
- BYSI.US
- ISIN
- KYG108301006
- Exchange
- USA Stocks
- Listed since
- Mar 9, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Fiscal year end
- December
- Address
- 100 Campus Drive, Florham Park, NJ, United States, 07932
- Phone
- 646 305 6387
- Website
- beyondspringpharma.com
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
BeyondSpring Inc management
7- Dr. Lan Huang Ph.D.Co-Founder & Chair of the Board · born 1971
- Dr. June Lu Ph.D.Chief Scientific Officer · born 1966
- Mr. Min QiuChief Executive Officer · born 1983
- Ms. Li NaChief Financial Officer · born 1977
- Stephen KilmerHead of Investor Relations
- Dr. John Mao Ph.D.Senior Vice President of Development
- Ms. Joy JiaVice President of Finance